The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

The recommendations were made in a closed session with representatives from CBER, the CDC and Department of Defense.

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

As Marty Makary and Jay Bhattacharya sail through the Senate health committee vote, Weldon's confirmation hearing is canceled ...

While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to ...

In this episode of Denatured, BioSpace's Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss the challenges of ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the ...

Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, ...